← Leaderboards
David M Charytan
New York University School Of Medicine
$9,989,819
Attributed
$17,153,257
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,153,257 · 10
By mechanism
R01$7,661,370 · 4
U01$4,793,606 · 2
R44$2,985,949 · 1
R21$950,682 · 2
R34$761,650 · 1
Top collaborators
- Charles A Herzog4 shared
- Jasmin Divers3 shared
- Finnian R Mccausland3 shared
- Girish Nitin Nadkarni3 shared
- Arno W Tilles3 shared
- Patrick H Pun2 shared
- Joshua D Lee1 shared
- Amanda J Shallcross1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Charles A Herzog$1,907,093
- Joshua D Lee$16,892,346
Others in their field
Top investigators on “Functional Disorder”
- Randall J Bateman · Washington University$164,791,794
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- David Heimbrook · Leidos Biomedical Research, Inc.$127,725,513
- Ed Lein · Allen Institute$92,850,604
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- John M Lachin · George Washington University$85,958,868
Research focus
Functional DisorderHigh RiskIncidenceCardiovascular SystemDesignDialysis ProcedureEnd Stage Renal FailureCessation Of LifeRisk FactorsCardiovascular Risk FactorUnited StatesMedicareLeadMortalityCaringEventExpenditureGeneral PopulationCardiovascular DiseasesLinkHemodialysisSafetyAdverse EventBase
Grant awards (28)
Deep learning on ECGs to improve outcomes in patients on dialysis$730,082
R01 · FY2025 · HL
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor$687,709
R01 · FY2025 · HL · contact PI
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$342,085
R01 · FY2025 · DK · contact PI
Deep learning on ECGs to improve outcomes in patients on dialysis$716,516
R01 · FY2024 · HL
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor$669,040
R01 · FY2024 · HL · contact PI
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$328,965
R01 · FY2024 · DK · contact PI
Deep learning on ECGs to improve outcomes in patients on dialysis$735,360
R01 · FY2023 · HL
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor$692,665
R01 · FY2023 · HL · contact PI
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$364,551
R01 · FY2023 · DK · contact PI
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor$740,651
R01 · FY2022 · HL · contact PI
Pain, Opioids, and ESRD risk reduction with Mindfulness and Buprenorphine (POEM-B): A 3-arm multi-site randomized trial in hemodialysis patients$2,883,251
U01 · FY2019 · DK · contact PI
Randomized trials using point of care-guided manipulation of dialysate potassium, dialysate bicarbonate, and ultrafiltration rate to prevent hemodilaysis-associated arrythmia$367,165
R34 · FY2019 · HL · contact PI
Randomized trials using point of care-guided manipulation of dialysate potassium, dialysate bicarbonate, and ultrafiltration rate to prevent hemodilaysis-associated arrythmia$394,485
R34 · FY2018 · HL · contact PI
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease$384,547
R01 · FY2017 · HL · contact PI
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$962,626
R44 · FY2016 · DK
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD$442,392
U01 · FY2016 · DK · contact PI
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease$422,778
R01 · FY2016 · HL · contact PI
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$1,006,437
R44 · FY2015 · DK
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD$558,770
U01 · FY2015 · DK · contact PI
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease$414,254
R01 · FY2015 · HL · contact PI
NO, myocardial fibrosis, and microvascular rarefaction in ESRD: Pilot Studies$265,715
R21 · FY2015 · DK · contact PI
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive$1,016,886
R44 · FY2014 · DK
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD$521,271
U01 · FY2014 · DK · contact PI
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease$432,167
R01 · FY2014 · HL · contact PI
NO, myocardial fibrosis, and microvascular rarefaction in ESRD: Pilot Studies$220,749
R21 · FY2014 · DK · contact PI
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD$387,922
U01 · FY2013 · DK · contact PI
CABG and PCI for the Treatment of CAD in Individuals with CKD$244,769
R21 · FY2011 · DK · contact PI
CABG and PCI for the Treatment of CAD in Individuals with CKD$219,449
R21 · FY2010 · DK · contact PI